Why the study?
To investigate the epidemiological burden of MASLD across CKM stages, evaluate its association with cardiovascular mortality, and explore the mediating role of insulin resistance.
Does the presence of MASLD increase cardiovascular mortality in adults with Cardiovascular-Kidney-Metabolic syndrome stages 1-4?
Population
9,093 adults with CKM stages 1–4 from NHANES (2009–2018)
Comparison
MASLD (usFLI ≥ 30) vs non-MASLD across CKM stages
Design
Retrospective cohort study using NHANES survey data
Authors
Loading...
Supports MASLD assessment in CKM syndrome risk stratification; leaves open causality and intervention effects.
Does the presence of MASLD increase cardiovascular mortality in adults with Cardiovascular-Kidney-Metabolic syndrome stages 1-4?
In patients with Cardiovascular-Kidney-Metabolic syndrome, MASLD is associated with a stage-dependent increase in prevalence and a 63% higher risk of cardiovascular mortality, with insulin resistance mediating a significant portion of this risk.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: